SAN DIEGO, California — AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the appointment of Dominic Piscitelli as chief financial officer. Mr. Piscitelli will play a key role in AnaptysBio's finance strategy, as well as overseeing the company's accounting and SEC reporting functions.

"We are pleased to welcome Dominic to the senior management team at AnaptysBio," said Hamza Suria, president & CEO of AnaptysBio. "His experience in biotech finance will play a key role in the strategic growth of AnaptysBio as we advance our wholly-owned pipeline programs. We look forward to working closely with Dominic to execute on AnaptysBio's long-term vision in developing antibody medicines for inflammatory diseases."

Prior to joining AnaptysBio, Mr. Piscitelli served as vice president of finance, strategy and investor relations at Medivation, Inc., and played in a key role in its acquisition by Pfizer. Between 2011 and 2012, Mr. Piscitelli served as senior director of collaborations and operations finance at Astellas Pharmaceuticals. From 2001 to 2011, Mr. Piscitelli served in various roles of increasing responsibility culminating as the vice president, treasury & management finance at OSI Pharmaceuticals, Inc., and played a significant role in its acquisition by Astellas Pharmaceuticals. Mr. Piscitelli holds bachelors and masters degrees in finance and is a licensed C.P.A.

"I am excited to join the AnaptysBio team during this stage in the company's growth," said Mr. Piscitelli. "AnaptysBio's antibody discovery and development expertise has allowed the company to build a clinical-stage product pipeline funded through equity financings and strategic partnerships."